NCT03744468: A reported trial by BeiGene
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03744468 |
|---|---|
| Title | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 13, 2018 |
| Completion date | Feb. 6, 2025 |
| Required reporting date | Feb. 6, 2026, midnight |
| Actual reporting date | Jan. 30, 2026 |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | None |